1. Cell Cycle/DNA Damage Autophagy Anti-infection Apoptosis
  2. Topoisomerase Autophagy Mitophagy Bacterial Apoptosis Antibiotic
  3. Etoposide

Etoposide  (Synonyms: VP-16; VP-16-213)

Cat. No.: HY-13629 Purity: 99.94%
COA Handling Instructions

Etoposide (VP-16; VP-16-213) est un agent de chimiothérapie anticancéreuse. Etoposide inhibe la topoisomérase II, il peut arrêter ainsi la réplication de l'ADN. Etoposide induit un arrêt du cycle cellulaire, l'apoptose et l'autophagie.

Etoposid (VP-16; VP-16-213) ist ein Anti-Krebs-Chemotherapeutikum. Etoposid hemmt die topoisomerase II und stoppt so die DNA-Replikation. Etoposid induziert Zellzyklus-Arrest, apoptosis und autophagy.

Etoposide (VP-16; VP-16-213) is an anti-cancer chemotherapy agent. Etoposide inhibits topoisomerase II, thus stopping DNA replication. Etoposide induces cell cycle arrest, apoptosis and autophagy.

For research use only. We do not sell to patients.

Etoposide Chemical Structure

Etoposide Chemical Structure

CAS No. : 33419-42-0

Size Price Stock Quantity
Free Sample (0.1 - 0.5 mg)   Apply Now  
Solid + Solvent
10 mM * 1 mL in DMSO
ready for reconstitution
USD 66 In-stock
Solution
10 mM * 1 mL in DMSO USD 66 In-stock
Solid
100 mg USD 60 In-stock
200 mg USD 84 In-stock
500 mg   Get quote  
1 g   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 98 publication(s) in Google Scholar

Other Forms of Etoposide:

Top Publications Citing Use of Products

79 Publications Citing Use of MCE Etoposide

WB
RT-PCR
IF
Proliferation Assay
Cell Viability Assay

    Etoposide purchased from MedChemExpress. Usage Cited in: Oncogene. 2023 Feb 2.  [Abstract]

    Etoposide (VP16; 5 mg/kg; s.c.; every two days for 8 days) strongly suppresses tumor growth in mice.

    Etoposide purchased from MedChemExpress. Usage Cited in: J Pharm Pharmacol. 2023 Mar 1;rgad007.  [Abstract]

    Irinotecan (CPT11; 20 μM; 48 h) or Etoposide (VP16; 20 μM; 48 h) induces MDA-MB-231 cells cycle arrest significantly.

    Etoposide purchased from MedChemExpress. Usage Cited in: Elife. 2022 May 3;11:e69255.  [Abstract]

    BCL6 mRNA expression in Etoposide (ETO)-resistant and -sensitive cells. Cells are treated with Etoposide at their respective 1/2 IC50s for 24 hr.

    Etoposide purchased from MedChemExpress. Usage Cited in: Elife. 2022 May 3;11:e69255.  [Abstract]

    Etoposide activated mTOR signaling components in Etoposide-resistant Capan-2 and PANC28 cells. Cells were treated with etoposide at their respective 1/2 IC50s for 6 or 12 hr. A long-term treatment with Etoposide activated mTOR signaling components in ETO-resistant cells. Capan-2 and PANC28 cells are treated with 10 μM Etoposide for 2 or 4 days.

    Etoposide purchased from MedChemExpress. Usage Cited in: Elife. 2022 May 3;11:e69255.  [Abstract]

    Cell sensitivity to Etoposide (ETO). Cancer cells are treated with etoposide at gradient concentrations for 48 hr.

    Etoposide purchased from MedChemExpress. Usage Cited in: Elife. 2022 May 3;11:e69255.  [Abstract]

    Etoposide induced BCL6 protein expression in a time-dependent manner. ETO-resistant or -sensitive cells are treated with etoposide at their respective 1/4 IC50s for 2, 4, or 6 days.

    Etoposide purchased from MedChemExpress. Usage Cited in: Elife. 2022 May 3;11:e69255.  [Abstract]

    STAT1 protein and its phosphorylation levels by immunoblotting analysis. Etoposide (ETO)-resistant and -sensitive cells are treated with Etoposide at their respective 1/2 IC50s for indicated time points.

    Etoposide purchased from MedChemExpress. Usage Cited in: Protein Cell. 2022 Jan;13(1):47-64.  [Abstract]

    FISH of telomeres on metaphase spreads to detect chromosome end-to-end fusions in 6 kb-HeLa treated with VP-16. Control (Scr) or cGAS-depleted cells (gcGAS-1, gcGAS-2) are either harvested immediately following treatment (VP-16, 2 μM, 1 h) or released for 4 h (Release 4 h) during mitosis.

    Etoposide purchased from MedChemExpress. Usage Cited in: Cell Death Dis. 2021 Mar 12;12(3):265.  [Abstract]

    Inhibition of PRDX1 increased the sensitivity of HCT116 cells to Etoposide-induced apoptosis: HCT116 cells infected with lentivirus expressing the indicated shRNAs were treated with 50 μM Etoposide for 0-6 h.

    Etoposide purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2020 Sep 28;7(21):2001364.  [Abstract]

    Lnc‐Ip53 attenuated the DNA damage- and oxidation stress-induced p53 acetylation at K382. Cells are incubated with 50 µM Etoposide (Eto) for 5 h.

    Etoposide purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2020 Sep 28;7(21):2001364.  [Abstract]

    Lnc‐Ip53 attenuated the DNA damage‐ and oxidation stress‐triggered increase of CDKN1A and PUMA. Cells are incubated with 50 µM Etoposide (Eto) for 6 h.

    Etoposide purchased from MedChemExpress. Usage Cited in: Hepatology. 2020 May;71(5):1660-1677.  [Abstract]

    Exposure to Etoposide (Eto), another DNA-damaging agent, induces PDIA3P1 expression, suggesting that PDIA3P1 may be up-regulated by DNA-damaging agents.

    Etoposide purchased from MedChemExpress. Usage Cited in: Theranostics. 2020 Jul 25;10(21):9477-9494.  [Abstract]

    Fibroblasts and HT-1080 cells are treated with 20 µM Etoposide or DMSO (vehicle group) for 2, 4, 8, 16, 24 and 36 h.

    Etoposide purchased from MedChemExpress. Usage Cited in: Theranostics. 2020 Jul 25;10(21):9477-9494.  [Abstract]

    When cells are treated with 20 µM Etoposide, an obvious increased green focus of RAD51 is observed in the treated fibroblasts using immunofluorescence (IF) staining.

    Etoposide purchased from MedChemExpress. Usage Cited in: Theranostics. 2020 Jul 25;10(21):9477-9494.  [Abstract]

    When cells are treated with 20 µM Etoposide or DMSO (vehicle group) for 4 h, western blots (WB) shows elevated expression of γH2AX, a marker of double-strand breaks (DSBs), in the Etoposide group.

    Etoposide purchased from MedChemExpress. Usage Cited in: EMBO Mol Med. 2020 Nov 6;12(11):e12525.  [Abstract]

    Immunoblot of PARP1 cleavage of PeTa cells after 6 days of indicated treatment. Etoposide (10 μM; for 24 h) serves as positive control for apoptosis, and H3 serves as loading control.

    Etoposide purchased from MedChemExpress. Usage Cited in: Aging Cell. 2020 Jul;19(7):e13171.  [Abstract]

    RPE p16‐mCherry cells were treated with DMSO, Etoposide (20 μM), H2O2 (200 μM), or serum starved for 24 hr.

    Etoposide purchased from MedChemExpress. Usage Cited in: Leuk Lymphoma. 2018 Jan;59(1):162-170.  [Abstract]

    WT1 and caspase-3 protein levels are detected in two primary AML blasts treated with 100 μM Eto for 24 h.

    Etoposide purchased from MedChemExpress. Usage Cited in: Cancer Lett. 2017 Nov 1;408:43-54.  [Abstract]

    Western blot analysis of p-p70S6k, p70S6k, p-AKT and AKT after 6 h of treatment with 20 μM RAD001. Levels of p-p70S6k and p-AKT are quantified by densitometric analysis and a corresponding histogram is constructed as relative to p70S6k or AKT and α-tubulin. The lower panel shows a representative Western blot.
    • Biological Activity

    • Purity & Documentation

    • References

    • Customer Review

    Description

    Etoposide (VP-16; VP-16-213) is an anti-cancer chemotherapy agent. Etoposide inhibits topoisomerase II, thus stopping DNA replication. Etoposide induces cell cycle arrest, apoptosis and autophagy[1].

    IC50 & Target[1]

    Topoisomerase II

     

    In Vitro

    Etoposide is capable of causing cytotoxicity on pancreatic β-cells by inducing apoptosis through the JNK/ERK-mediated GSK-3 downstream-triggered mitochondria-dependent signaling pathway in RIN-m5F cells[1].
    Etoposide and Anti-Human VEGF significantly abolish P1 sphere-forming ability, an effect associated with apoptosis of this subset of cells[2].
    Etoposide phosphate (0-1μM; 72 hours) inhibits HCT116 FBXW+/+, FBXW-/- and p53-/- as a dose-dependent manner, exhibits IC50s of 0.945 μM; 0.375 μM; and 1.437 μM, respectively[5].
    Etoposide (25 μM; 6 hours) delays p53 recover in FBXW7-deficient cells. In addition, FBXW7 expression is disappeared in FBXW7-/- cells[5].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    Cell Viability Assay[5]

    Cell Line: HCT116 FBXW+/+, FBXW-/- and p53-/- cells
    Concentration: 0.025 μM, 0.05 μM, 0.075 μM, 0.1 μM, 0.2 μM, 0.4 μM, 0.6 μM, 0.8 μM, 1 μM
    Incubation Time: 72 hours
    Result: Inhibits HCT116 FBXW+/+p>, FBXW-/- and p53-/- cell growth as a concentration manner.

    Western Blot Analysis[5]

    Cell Line: HCT116 FBXW7+/+ or FBXW7-/- cells
    Concentration: 25 μM
    Incubation Time: 6 hours
    Result: Exhibited that the recovery of p53 levels after DNA damage is mediated by FBXW7.
    In Vivo

    Etoposide (50 μM) and Anti-Human VEGF-treated hypoxic cells injected intravenously into immunodeficient mice reveals a reduced capacity to induce lung colonies, which also appear with a longer latency period[2]. Etoposide (10 mg/kg/day, i.v.) with NSC 109724 and NSC 241240, reduces the tumor volume in the hepatoblastoma cell injected NMRI nude mice[3].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    Clinical Trial
    Molecular Weight

    588.56

    Formula

    C29H32O13

    CAS No.
    Appearance

    Solid

    Color

    White to off-white

    SMILES

    O=C1OC[C@]2([H])[C@H](O[C@H]3[C@@H]([C@H]([C@@H]4O[C@H](C)OC[C@H]4O3)O)O)C5=C(C=C6OCOC6=C5)[C@@H](C7=CC(OC)=C(O)C(OC)=C7)[C@]21[H]

    Structure Classification
    Initial Source
    Shipping

    Room temperature in continental US; may vary elsewhere.

    Storage

    4°C, protect from light

    *In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

    Solvent & Solubility
    In Vitro: 

    DMSO : ≥ 39 mg/mL (66.26 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

    *"≥" means soluble, but saturation unknown.

    Preparing
    Stock Solutions
    Concentration Solvent Mass 1 mg 5 mg 10 mg
    1 mM 1.6991 mL 8.4953 mL 16.9906 mL
    5 mM 0.3398 mL 1.6991 mL 3.3981 mL
    View the Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

    • Molarity Calculator

    • Dilution Calculator

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    Mass
    =
    Concentration
    ×
    Volume
    ×
    Molecular Weight *

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    Concentration (start)

    C1

    ×
    Volume (start)

    V1

    =
    Concentration (final)

    C2

    ×
    Volume (final)

    V2

    In Vivo:

    Select the appropriate dissolution method based on your experimental animal and administration route.

    For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
    To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
    The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

    • Protocol 1

      Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

      Solubility: ≥ 2.5 mg/mL (4.25 mM); Clear solution

      This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

      Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

      Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
    • Protocol 2

      Add each solvent one by one:  10% DMSO    90% Corn Oil

      Solubility: ≥ 2.5 mg/mL (4.25 mM); Clear solution

      This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

      Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

    In Vivo Dissolution Calculator
    Please enter the basic information of animal experiments:

    Dosage

    mg/kg

    Animal weight
    (per animal)

    g

    Dosing volume
    (per animal)

    μL

    Number of animals

    Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
    Please enter your animal formula composition:
    %
    DMSO +
    +
    %
    Tween-80 +
    %
    Saline
    Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
    The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
    Calculation results:
    Working solution concentration: mg/mL
    Method for preparing stock solution: mg drug dissolved in μL  DMSO (Stock solution concentration: mg/mL).

    *In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

    The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
    Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.
     If the continuous dosing period exceeds half a month, please choose this protocol carefully.
    Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
    Purity & Documentation

    Purity: 99.94%

    References

    Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

    Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
    DMSO 1 mM 1.6991 mL 8.4953 mL 16.9906 mL 42.4766 mL
    5 mM 0.3398 mL 1.6991 mL 3.3981 mL 8.4953 mL
    10 mM 0.1699 mL 0.8495 mL 1.6991 mL 4.2477 mL
    15 mM 0.1133 mL 0.5664 mL 1.1327 mL 2.8318 mL
    20 mM 0.0850 mL 0.4248 mL 0.8495 mL 2.1238 mL
    25 mM 0.0680 mL 0.3398 mL 0.6796 mL 1.6991 mL
    30 mM 0.0566 mL 0.2832 mL 0.5664 mL 1.4159 mL
    40 mM 0.0425 mL 0.2124 mL 0.4248 mL 1.0619 mL
    50 mM 0.0340 mL 0.1699 mL 0.3398 mL 0.8495 mL
    60 mM 0.0283 mL 0.1416 mL 0.2832 mL 0.7079 mL
    • No file chosen (Maximum size is: 1024 Kb)
    • If you have published this work, please enter the PubMed ID.
    • Your name will appear on the site.
    Help & FAQs
    • Do most proteins show cross-species activity?

      Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

    Your Recently Viewed Products:

    Inquiry Online

    Your information is safe with us. * Required Fields.

    Product Name

     

    Salutation

    Applicant Name *

     

    Email Address *

    Phone Number *

     

    Organization Name *

    Department *

     

    Requested quantity *

    Country or Region *

         

    Remarks

    Bulk Inquiry

    Inquiry Information

    Product Name:
    Etoposide
    Cat. No.:
    HY-13629
    Quantity:
    MCE Japan Authorized Agent: